Category: Publication
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Precision Dosing in Clinical Medicine: Present and Future
A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole
Pharmacodynamic Analysis of Eribulin Safety in Breast Cancer Patients Using Real-world Postmarketing Surveillance Data
Pharmacokinetics of Praziquantel in Schistosoma Mansoni- and Schistosoma Haematobium-infected School- and Preschool-aged Children
Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond
Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly binds to the active site of FXa, and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin. Apixaban is approved in multiple regions for VTEtx, based on the results of a Phase 3 study (AMPLIFY [1]). … Continued